Immuno oncology News and Research

RSS

Cardio3 BioSciences reports absence of short term adverse events in first patient following NKG2D CAR T-cell infusion

Cardio3 BioSciences, soon to be renamed Celyad, a leader in engineered cell-therapy treatments today announced the infusion of the first patient enrolled in the Company’s Phase I clinical trial evaluating the safety and feasibility of its NKG2D CAR T-cell therapy, in cancer patients suffering from acute myeloid leukemia (AML) or multiple myeloma (MM).

22 Apr 2015

MD Anderson, NanoString Technologies collaborate to accelerate development of 'multi-omic' assays

The University of Texas MD Anderson Cancer Center and NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced a multi-year collaboration to accelerate the development and adoption of a new type of assay based on NanoString's nCounter Analysis System.

From NanoString Technologies 1 Apr 2015

Merck Serono, Intrexon partner to develop and commercialize CAR-T cancer therapies

Merck Serono, the biopharmaceutical business of Merck, and Intrexon Corporation, today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies.

30 Mar 2015

CRT, BioInvent, and University of Southampton partner to develop new immunotherapy treatments for cancer

Cancer Research Technology, the commercialization and development arm of Cancer Research UK and BioInvent International today announce the start of a two-year research collaboration with leading antibody researchers at the University of Southampton.

30 Mar 2015

Taconic, Cellaria partner to facilitate use of patient-derived xenografts for oncology research

Taconic Biosciences and Cellaria Biosciences today announced that the two companies have entered into a scientific collaboration designed to facilitate and improve the utility of patient-derived xenografts (PDXs) in animal models for oncology and immuno-oncology research. Cellaria’s novel methodologies for generating cells from patient tumors will complement Taconic’s industry-leading portfolio of tissue humanized mouse models, which are well-suited as hosts for PDXs.

27 Mar 2015

BeyondSpring files two patent applications to expand therapeutic scope of Plinabulin

BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed two new method of treatment patent applications with the United States Patent and Trademark Office to cover methods of treating brain tumors as well as cancers expressing a mutant form of RAS protein through administration of the Company’s lead compound, Plinabulin.

26 Mar 2015

Eli Lilly, Innovent Biologics announce biotech drug development collaborations in China

Eli Lilly and Company and Innovent Biologics, Inc. today announced one of the largest biotech drug development collaborations in China to date between a multi-national and domestic company.

21 Mar 2015

NantWorks, Sorrento collaborate to discover and develop novel anti-cancer immunotherapies

NantWorks, Inc. and Sorrento Therapeutics, Inc., announced today that they have entered into a binding agreement to initiate a global collaboration to discover and develop novel anti-cancer immunotherapies derived from Sorrento's proprietary G-MAB library against neoepitopes of tumor-specific antigens discovered using NantWorks' proprietary pan-omics based, precision medicine approach.

16 Mar 2015

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Company today announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors.

23 Feb 2015

Crown Bioscience, NRCMM partner to develop new immune-oncology experimental cancer models

Crown Bioscience, Inc., a leading global drug discovery and development service company with its R&D centers across the globe has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice and its commercial branch Nanjing Biotech Innovation Corporation, in Nanjing, Jiangsu Province, China.

6 Feb 2015

Intrexon and ZIOPHARM Oncology sign exclusive licensing agreement with MD Anderson

Intrexon Corporation, a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology, today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.

14 Jan 2015

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Merck, known as MSD outside of Canada and the United States, announced today early study findings demonstrating that patients treated with pembrolizumab, the company's investigational anti-PD-1 cancer therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82).

7 Dec 2014

Experimental drug works best when patients' immune cells surrounding tumors express PD-L1

A promising experimental immunotherapy drug works best in patients whose immune defenses initially rally to attack the cancer but then are stymied by a molecular brake that shuts down the response, according to a new study led by researchers at Dana-Farber Cancer Institute and the Yale University School of Medicine.

28 Nov 2014

Research: HD-IL2 can be effective in mRCC patients pre-treated with VEGF-targeted agents

High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented today at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland.

24 Nov 2014

Research shows that immune checkpoint inhibitors may work in glioblastoma, brain metastases

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

23 Nov 2014

Epicure project: an interview with Frédéric Cren

Epicure is a project led by Inventiva and Institut Curie that aims to deliver pre-clinical candidates on two novel epigenetic targets that have been selected due to their potential to activate immune responses against cancer cells. In addition one of these two targets has potential in respiratory indications such as asthma or COPD.

3 Nov 2014

Bristol-Myers Squibb, MD Anderson partner to evaluate multiple immunotherapies

Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center today announced a novel clinical research collaboration to evaluate multiple immunotherapies, including Opdivo (nivolumab), Yervoy (ipilimumab) and three early-stage clinical immuno-oncology assets from Bristol-Myers Squibb, as potential treatment options for acute and chronic leukemia as well as other hematologic malignancies.

6 Oct 2014

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

New immuno-oncology drug helps body's own immune system to fend off cancer

According to an August 25 Reuters report, the U.S. Food and Drug Administration is likely to approve Merck & Co.'s highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline.

8 Sep 2014

Ludwig, CRI collaborate with VentiRx to conduct clinical trial with motolimod and immunotherapy agents

The nonprofits Ludwig Cancer Research (Ludwig) and the Cancer Research Institute (CRI) announced today an agreement with VentiRx Pharmaceuticals Inc., a clinical stage biopharmaceutical company, to conduct a clinical trial with motolimod (VTX-2337) combined with other immunotherapy agents available to Ludwig and CRI through other industry partnerships.

4 Sep 2014